| Minoxidil (low-dose oral) High· 3 trials | Not recorded | Marketed, off-label | Oral | Potassium channel opener | Sep 2026 |
| Baricitinib (Olumiant) High· 8 trials | Eli Lilly | Approved | Oral | JAK inhibitor | Sep 2026 |
| Deuruxolitinib (Leqselvi) High· 10 trials | Sun Pharmaceutical | Approved | Oral | JAK inhibitor | Sep 2026 |
| Dutasteride (Avodart / Zagallo) High· 7 trials | GSK | Approved | Oral | 5α-reductase inhibitor | Mar 2026 |
| Finasteride (Propecia) High· 4 trials | Organon | Approved | Oral | 5α-reductase inhibitor | Dec 2025 |
| Jaktinib High· 4 trials | Suzhou Zelgen Biopharmaceuticals | Approved | OralTopical | JAK inhibitor | Mar 2025 |
| Minoxidil (topical) High· 25 trials | Not recorded | Approved | Topical | Potassium channel opener | Sep 2026 |
| Ritlecitinib (Litfulo) High· 16 trials | Pfizer | Approved | Oral | JAK inhibitor | Sep 2026 |
| Topical finasteride High· 4 trials | Almirall | Approved | Topical | 5α-reductase inhibitor | Feb 2025 |
| Upadacitinib (Rinvoq) High· 4 trials | AbbVie | Approved | Oral | JAK inhibitor | Oct 2026 |
| Ivarmacitinib (ARQ-252) Medium· 2 trials | Not recorded | Filed with regulator | Oral | JAK inhibitor | ◷Nothing new since Sep 2023 |
| AD-208 (low-dose dutasteride) Medium· 2 trials | Addpharma | Phase 3 | Oral | 5α-reductase inhibitor | ◷Nothing new since Jul 2023 |
| APSMNF Low· 1 trial | Apsen Farmacêutica | Phase 3 | Other | Undisclosed | Sep 2026 |
| CKD-843 Medium· 3 trials | Chong Kun Dang Pharmaceutical | Phase 3 | Injectable | 5α-reductase inhibitor | Sep 2026 |
| Clascoterone (Breezula) High· 3 trials | Cosmo Pharmaceuticals | Phase 3 | Topical | Androgen receptor | Jun 2026 |
| N1087 (oral minoxidil) Medium· 1 trial | Eurofarma Laboratórios | Phase 3 | Oral | Potassium channel opener | Jan 2026 |
| OMA102 Low· 1 trial | EMS | Phase 3 | Oral | Undisclosed | ◷Nothing new since Feb 2024 |
| Pyrilutamide High· 7 trials | Kintor Pharmaceutical | Phase 3 | Topical | Androgen receptor | ◷Nothing new since Oct 2024 |
| TH07 Low· 1 trial | Triple Hair | Phase 3 | Topical | Combination | Mar 2026 |
| VDPHL-01 (oral minoxidil) Medium· 4 trials | Veradermics | Phase 3 | Oral | Potassium channel opener | Aug 2026 |
| Brepocitinib Medium· 2 trials | Priovant Therapeutics | Phase 2/3 | Oral | JAK inhibitor | May 2026 |
| Coacillium (LH-8) High | Legacy Healthcare | Phase 2/3 | Topical | Other | No trials on record |
| Dalosirvat (SM-04554) Medium· 3 trials | Biosplice Therapeutics | Phase 2/3 | Topical | Wnt pathway | Oct 2026 |
| Bempikibart (ADX-914) High· 1 trial | Q32 Bio | Phase 2 | BiologicInjectable | Immunomodulator | May 2026 |
| CKD-498 Low· 1 trial | Chong Kun Dang Pharmaceutical | Phase 2 | Oral | Undisclosed | ◷Nothing new since Jun 2024 |
| Delgocitinib (LEO 124249) High· 5 trials | LEO Pharma | Phase 2 | Topical | JAK inhibitor | Aug 2026 |
| Deucravacitinib High· 2 trials | Bristol Myers Squibb | Phase 2 | Oral | JAK inhibitor | Jul 2026 |
| ENERGI-F701 Medium· 1 trial | Energenesis Biomedical | Phase 2 | Topical | Metabolic / mitochondrial | ◷Nothing new since Nov 2020 |
| GT20029 Medium· 3 trials | Kintor Pharmaceutical | Phase 2 | Topical | Androgen receptor | ◷Nothing new since Nov 2024 |
| HMI-115 Medium· 2 trials | Hope Medicine | Phase 2 | InjectableBiologic | Prolactin receptor | Jun 2025 |
| LAD603 Low· 1 trial | Almirall | Phase 2 | Injectable | Undisclosed | May 2026 |
| LY4005130 Low· 1 trial | Eli Lilly | Phase 2 | Injectable | Undisclosed | Sep 2026 |
| NXC736 Low· 1 trial | NEXTGEN Bioscience | Phase 2 | Oral | Immunomodulator | Apr 2026 |
| Olevaprubart (IMG-007) High· 1 trial | ImageneBio | Phase 2 | BiologicInjectable | Immunomodulator | Feb 2026 |
| PDFE-2304 (Neopili) Low· 1 trial | PDFE Pharma Innovations | Phase 2 | Topical | Undisclosed | Jun 2025 |
| PP405 High· 2 trials | Pelage Pharmaceuticals | Phase 2 | Topical | Metabolic / mitochondrial | Oct 2026 |
| Rezpegaldesleukin (REZPEG) High· 1 trial | Nektar Therapeutics | Phase 2 | BiologicInjectable | Immunomodulator | Sep 2026 |
| STS01 Medium· 1 trial | Soterios Pharma | Phase 2 | Topical | Undisclosed | ◷Nothing new since May 2024 |
| SYHX1901 Low· 1 trial | CSPC Pharmaceutical Group | Phase 2 | Oral | JAK inhibitor | Jun 2025 |
| TDM-105795 Medium· 4 trials | TechnoDerma Medicines | Phase 2 | Topical | Thyroid hormone receptor | Nov 2025 |
| VC005 Low· 2 trials | Jiangsu Vcare Pharmaceutical | Phase 2 | Oral | JAK inhibitor | Aug 2026 |
| ABS-201 High· 1 trial | Absci | Phase 1/2 | BiologicInjectable | Prolactin receptor | Sep 2026 |
| AD-303 (topical dutasteride) Low· 1 trial | Moogene Medi | Phase 1/2 | Topical | 5α-reductase inhibitor | Mar 2026 |
| ALD-102 Medium· 1 trial | Aldena Therapeutics | Phase 1/2 | Injectable | RNA interference | Mar 2026 |
| DA-001 / DA-002 / DA-005 Medium· 6 trials | Applied Biology | Phase 1/2 | Topical | Adrenergic | Aug 2026 |
| DLQ-01 (latanoprost) Medium· 1 trial | DermaLiq Therapeutics | Phase 1/2 | Topical | Prostaglandin | ◷Nothing new since Apr 2024 |
| Epibiotech dermal papilla cell therapy Medium· 1 trial | Epibiotech | Phase 1/2 | Cell therapyInjectable | Stem cell activation | Jun 2026 |
| IVL3001 Medium· 1 trial | Inventage Lab | Phase 1/2 | Injectable | 5α-reductase inhibitor | ◷Nothing new since Mar 2022 |
| OLX104C (OLX72021) Medium· 1 trial | Olix Pharmaceuticals | Phase 1/2 | Injectable | RNA interference | Mar 2026 |
| Xvie (amniotic fluid injectable) Medium· 2 trials | Xtressé | Phase 1/2 | BiologicInjectable | Growth factor | Aug 2026 |
| AMP-303 Medium | Amplifica | Phase 1 | Injectable | Other | No trials on record |
| ANR-001.1 (latanoprost + minoxidil) Low | Aneira Pharma | Phase 1 | Topical | Combination | No trials on record |
| ET-02 Medium | Eirion Therapeutics | Phase 1 | Topical | Stem cell activation | No trials on record |
| HairClone follicle banking & cell therapy Medium | HairClone | Phase 1 | Cell therapy | Stem cell activation | No trials on record |
| OrganTech / Tsuji follicular primordium Low | OrganTech | Preclinical | Hair cloning & follicle neogenesis | Stem cell activation | No trials on record |
| TissUse Smart Hair Transplant Low | TissUse | Preclinical | Hair cloning & follicle neogenesisSurgical | Stem cell activation | No trials on record |